| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DXCM | Common Stock | Other | $0 | -2.5K | -15.09% | $0.00 | 14.1K | Sep 9, 2021 | Direct | F1, F2 |
| transaction | DXCM | Common Stock | Other | $0 | +2.5K | +23.45% | $0.00 | 13.2K | Sep 9, 2021 | by Trust | F1, F3 |
| transaction | DXCM | Common Stock | Sale | -$676K | -1.25K | -9.49% | $541.36 | 11.9K | Sep 9, 2021 | by Trust | F3, F4 |
| transaction | DXCM | Common Stock | Sale | -$8.13K | -15 | -0.13% | $541.76 | 11.9K | Sep 9, 2021 | by Trust | F3, F4 |
| transaction | DXCM | Common Stock | Sale | -$148K | -273 | -2.3% | $541.33 | 11.6K | Sep 9, 2021 | by Trust | F3, F5, F6 |
| transaction | DXCM | Common Stock | Sale | -$109K | -200 | -1.72% | $542.83 | 11.4K | Sep 9, 2021 | by Trust | F3, F5, F7 |
| transaction | DXCM | Common Stock | Sale | -$27.2K | -50 | -0.44% | $543.66 | 11.4K | Sep 9, 2021 | by Trust | F3, F5 |
| transaction | DXCM | Common Stock | Sale | -$301K | -550 | -4.84% | $547.35 | 10.8K | Sep 9, 2021 | by Trust | F3, F5, F8 |
| transaction | DXCM | Common Stock | Sale | -$411K | -750 | -6.94% | $548.24 | 10.1K | Sep 9, 2021 | by Trust | F3, F5, F9 |
| transaction | DXCM | Common Stock | Sale | -$693K | -1.26K | -12.53% | $549.43 | 8.8K | Sep 9, 2021 | by Trust | F3, F5, F10 |
| transaction | DXCM | Common Stock | Sale | -$660K | -1.2K | -13.63% | $550.36 | 7.6K | Sep 9, 2021 | by Trust | F3, F5, F11 |
| transaction | DXCM | Common Stock | Sale | -$27.6K | -50 | -0.66% | $551.45 | 7.55K | Sep 9, 2021 | by Trust | F3, F5 |
| Id | Content |
|---|---|
| F1 | Shares were transferred from direct ownership to ownership under the Balo Family Trust upon vesting of previously awarded restricted stock units. |
| F2 | Included in this number are 13,673 unvested restricted stock units, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,498 of which were granted on March 8, 2019 and shall vest through March 8, 2022. |
| F3 | Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee. |
| F4 | Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| F5 | On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. |
| F6 | This transaction was executed in multiple trades at prices ranging from $541.27 to $541.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. |
| F7 | This transaction was executed in multiple trades at prices ranging from $542.55 to $543.40. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. |
| F8 | This transaction was executed in multiple trades at prices ranging from $546.745 to $547.740. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. |
| F9 | This transaction was executed in multiple trades at prices ranging from $547.80 to $548.65. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. |
| F10 | This transaction was executed in multiple trades at prices ranging from $548.93 to $549.92. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. |
| F11 | This transaction was executed in multiple trades at prices ranging from $549.99 to $550.73. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. |
*EVP Regulatory Strategy Clinical Affairs and Strategic Partnership Development